During the last session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares were 1.76 million, with the beta value of the company hitting 1.36. At the end of the trading day, the stock’s price was $1.60, reflecting an intraday loss of -0.62% or -$0.01. The 52-week high for the LXRX share is $3.79, that puts it down -136.88 from that peak though still a striking 42.5% gain since the share price plummeted to a 52-week low of $0.92. The company’s market capitalization is $393.98M, and the average trade volume was 4.75 million shares over the past three months.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Lexicon Pharmaceuticals Inc (LXRX) registered a -0.62% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.62% in intraday trading to $1.60, hitting a weekly high. The stock’s 5-day price performance is -1.23%, and it has moved by -24.53% in 30 days. Based on these gigs, the overall price performance for the year is -32.49%.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Statistics show that Lexicon Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Lexicon Pharmaceuticals Inc (LXRX) shares have gone up 46.79% during the last six months, with a year-to-date growth rate less than the industry average at 10.13% against 12.90. In the rating firms’ projections, revenue will increase 2,043.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.37M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 2.97M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 6.80%. While earnings are projected to return 10.13% in 2024.
LXRX Dividends
Lexicon Pharmaceuticals Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
